Key result
Triple-combination fimasartan, amlodipine, and hydrochlorothiazide shows bioequivalence and similar tolerability to loose combination.
Why the study?
Does a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg have similar pharmacokinetic profiles compared to a loose combination in healthy subjects?
Does a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg have similar pharmacokinetic profiles compared to a loose combination in healthy subjects?
Answers are grounded in this paper and cite their sources.
A fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg provides similar pharmacokinetic exposure to the loose combination, supporting its potential use as a convenient single-pill option.
, respectively. Both the FDC and loose combinations were well tolerated. In conclusion, the FDC of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg showed similar PK profiles to those of the corresponding loose combination, and both treatments were well tolerated.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2021) studied this question. A fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/ showed similar pharmacokinetic profiles and tolerability to the corresponding loose combination.
Synapse has enriched 10 related papers. Consider them for comparative context: